<SEC-DOCUMENT>0001347178-20-000022.txt : 20200805
<SEC-HEADER>0001347178-20-000022.hdr.sgml : 20200805
<ACCEPTANCE-DATETIME>20200805160602
ACCESSION NUMBER:		0001347178-20-000022
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20200805
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200805
DATE AS OF CHANGE:		20200805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vanda Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001347178
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				030491827
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34186
		FILM NUMBER:		201077259

	BUSINESS ADDRESS:	
		STREET 1:		2200 PENNSYLVANIA AVE NW
		STREET 2:		SUITE 300E
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037
		BUSINESS PHONE:		202-734-3400

	MAIL ADDRESS:	
		STREET 1:		2200 PENNSYLVANIA AVE NW
		STREET 2:		SUITE 300E
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>vnda-20200805.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:8dc27823-325f-4e18-a8bf-4ae4d4682f1f,g:d7a0f35e-3370-4959-8359-07fbdf7e30e6,d:5ff2037d672e4aa6953e6a31666a0d19--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vnda-20200805</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV80L2ZyYWc6YmM1MTk2MDMxMWYwNDgyYmJkNDY1MDk1NjZhZTY0MTMvdGFibGU6OTFjYzc3NjZiNGEyNGEyYzkzMTU5ZmRlOGFkM2I2NWEvdGFibGVyYW5nZTo5MWNjNzc2NmI0YTI0YTJjOTMxNTlmZGU4YWQzYjY1YV8yLTEtMS0xLTA_5ed66de5-734d-4c6f-a887-ad503d8cb1ce">0001347178</ix:nonNumeric><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV80L2ZyYWc6YmM1MTk2MDMxMWYwNDgyYmJkNDY1MDk1NjZhZTY0MTMvdGFibGU6OTFjYzc3NjZiNGEyNGEyYzkzMTU5ZmRlOGFkM2I2NWEvdGFibGVyYW5nZTo5MWNjNzc2NmI0YTI0YTJjOTMxNTlmZGU4YWQzYjY1YV8zLTEtMS0xLTA_42375de3-0d11-46bd-8ff6-9dc5b428b1e4">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vnda-20200805.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5ff2037d672e4aa6953e6a31666a0d19_1"></div><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-top:4pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:25.292%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">FORM&#160;<ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzc1_560fd78e-551d-466f-9b60-21af5325c17e">8-K</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:25.292%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CURRENT REPORT</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Pursuant to Section&#160;13 or 15(d)&#160;of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">the Securities Exchange Act of 1934</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8yMTk5MDIzMjU2OTM1_4eadf342-5607-41c1-a01c-7d0f46abe156">August&#160;5, 2020</ix:nonNumeric> </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:25.292%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzgw_ece8370b-e912-4159-a428-cc2deb9788d1">VANDA PHARMACEUTICALS INC.</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Exact name of Registrant as specified in its charter)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:25.292%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%;"><tr><td style="width:1.0%;"></td><td style="width:33.312%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.408%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:26.158%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.408%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:33.314%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6MjE4MWVhYTFjY2QzNDJhODk0NzY4ZmNkOGZjZjcyNTAvdGFibGVyYW5nZToyMTgxZWFhMWNjZDM0MmE4OTQ3NjhmY2Q4ZmNmNzI1MF8wLTAtMS0xLTA_c0871f35-9151-4059-bdf9-d9eb24fce35a">001-34186</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6MjE4MWVhYTFjY2QzNDJhODk0NzY4ZmNkOGZjZjcyNTAvdGFibGVyYW5nZToyMTgxZWFhMWNjZDM0MmE4OTQ3NjhmY2Q4ZmNmNzI1MF8wLTItMS0xLTcx_de2729bd-cdea-4b9d-8243-46909227392b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6MjE4MWVhYTFjY2QzNDJhODk0NzY4ZmNkOGZjZjcyNTAvdGFibGVyYW5nZToyMTgxZWFhMWNjZDM0MmE4OTQ3NjhmY2Q4ZmNmNzI1MF8wLTItMS0xLTA_f4a3b610-f688-40cf-aa71-1617dcde0a59">03-0491827</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Commission File No.)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(IRS Employer Identification No.)</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzc3_bd8a575b-8e3a-4d68-a025-59d915ede71a">2200 Pennsylvania Avenue NW</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzcy_ca311536-5ac5-4226-8f17-1fcff38de8d3">Suite 300E</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzcz_8ce5c6af-a4d3-4176-993b-0145ddb03aa9">Washington</ix:nonNumeric>, <ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzc0_4ae81f84-3067-4c76-a8e6-07bd2bfda3e8">DC</ix:nonNumeric> <ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF80NDA_d7b89baf-9168-40a2-9e60-d8fdcd37241d">20037</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Address of principal executive offices and zip code)</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF81NTA_0a7ea9f0-29b9-4695-8694-9c0a62b93d43">202</ix:nonNumeric>) <ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzc4_9f60cab1-9fd8-4a25-86a3-b630b326ca1f">734-3400</ix:nonNumeric></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Not Applicable</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Former Name or Former Address, if Changed Since Last Report)</span></td></tr></table></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:25.292%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:0.1%;"></td><td style="width:2.728%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.072%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6YTJhMGI2ZjA5NDcyNDYwYjgyODNiMDE2NDMyNjViNWMvdGFibGVyYW5nZTphMmEwYjZmMDk0NzI0NjBiODI4M2IwMTY0MzI2NWI1Y18wLTAtMS0xLTA_5c02c64b-07ed-4b04-88c1-97c4a1b70e12">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6YTJhMGI2ZjA5NDcyNDYwYjgyODNiMDE2NDMyNjViNWMvdGFibGVyYW5nZTphMmEwYjZmMDk0NzI0NjBiODI4M2IwMTY0MzI2NWI1Y18yLTAtMS0xLTA_9449501b-3a6a-4ace-ae28-3811bac32f9d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6YTJhMGI2ZjA5NDcyNDYwYjgyODNiMDE2NDMyNjViNWMvdGFibGVyYW5nZTphMmEwYjZmMDk0NzI0NjBiODI4M2IwMTY0MzI2NWI1Y180LTAtMS0xLTA_96cdc727-030b-42ec-a025-fc73a04079b9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6YTJhMGI2ZjA5NDcyNDYwYjgyODNiMDE2NDMyNjViNWMvdGFibGVyYW5nZTphMmEwYjZmMDk0NzI0NjBiODI4M2IwMTY0MzI2NWI1Y182LTAtMS0xLTA_84b21cb3-186d-4a4b-8d39-db6b4b125335">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:35.042%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.915%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.043%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Trading Symbol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6YmVjYzZmMjMyMWVhNDI0OWJjMzE5ZjY0YTIyNzllOWMvdGFibGVyYW5nZTpiZWNjNmYyMzIxZWE0MjQ5YmMzMTlmNjRhMjI3OWU5Y18xLTAtMS0xLTA_f1a2599b-a1da-49e8-8eba-bd33d3711d5b">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6YmVjYzZmMjMyMWVhNDI0OWJjMzE5ZjY0YTIyNzllOWMvdGFibGVyYW5nZTpiZWNjNmYyMzIxZWE0MjQ5YmMzMTlmNjRhMjI3OWU5Y18xLTEtMS0xLTA_fcd52ec1-11a3-4808-8755-d1f9d3ab3137">VNDA</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6YmVjYzZmMjMyMWVhNDI0OWJjMzE5ZjY0YTIyNzllOWMvdGFibGVyYW5nZTpiZWNjNmYyMzIxZWE0MjQ5YmMzMTlmNjRhMjI3OWU5Y18xLTItMS0xLTA_4f8a1079-bfe7-4e81-8b91-a7335424c688">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Emerging growth company&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzc5_b0035940-5764-4d9c-9417-81fe3af318b4">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#168;</span></div><div style="margin-top:4pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><div id="i5ff2037d672e4aa6953e6a31666a0d19_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:4pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:7.530%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:87.737%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;2.02.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Results of Operations and Financial Condition.</span></td></tr></table></div><div style="margin-top:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August&#160;5, 2020, Vanda Pharmaceuticals Inc. (&#8220;Vanda&#8221;) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended June 30, 2020. The full text of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Various statements to be made during the conference call are &#8220;forward-looking statements&#8221; under the securities laws, including, but not limited to, Vanda&#8217;s financial guidance for 2020. Words such as, but not limited to, &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;likely,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and &#8220;could,&#8221; or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Important factors that could cause actual results to differ materially from those reflected in Vanda&#8217;s forward-looking statements include, among others: Vanda&#8217;s assumptions regarding its ability to continue to grow its business in the U.S.; Vanda&#8217;s ability to minimize the disruption caused by, and maintain business continuity during, the global COVID-19 pandemic and related market volatility; the duration and severity of the global COVID-19 pandemic, including prevailing economic conditions and general uncertainties relating thereto that may be unknown and unforeseeable; Vanda&#8217;s ability to enroll patients in and complete its gastroparesis, motion sickness and ODYSSEY studies; Vanda&#8217;s ability to complete the clinical development and obtain regulatory approval for tradipitant in the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 Acute Respiratory Distress Syndrome; Vanda&#8217;s ability to successfully resume the clinical programs that are currently on hold and the U.S. Food and Drug Administration&#8217;s ability to complete its review of the HETLIOZ</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> applications for the treatment of Smith-Magenis Syndrome (&#8220;SMS&#8221;) on time and make the determination that HETLIOZ</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is safe and effective in the treatment of SMS in adults and children. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved. Forward-looking statements made during the conference call should be evaluated together with the various risks and uncertainties that affect Vanda&#8217;s business and market, particularly those identified in the &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;, &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of Vanda&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as updated by Vanda&#8217;s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">www.sec.gov</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. The information contained in this current report on Form 8-K is intended to be considered in the context of Vanda&#8217;s filings with the SEC and other public announcements that Vanda makes, by press release or otherwise, from time to time. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information conveyed on the conference call will be provided only as of the date of the call, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements made during the call after the date thereof, whether as a result of new information, future events or otherwise, except as required by law.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information in Item 2.02 of this current report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:7.530%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:87.737%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;9.01.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Statements and Exhibits.</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-9pt;padding-left:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt;">Exhibits</span></div><div style="text-indent:9pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:12.076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.706%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:82.018%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit&#160;No.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="vnda8-k8520exhibit991.htm">Press release of Vanda Pharmaceuticals Inc. dated August 5, 2020.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><div id="i5ff2037d672e4aa6953e6a31666a0d19_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:4.499%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:30.939%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.169%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.124%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:44.531%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 5, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VANDA PHARMACEUTICALS INC.</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Timothy Williams</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Timothy Williams</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Senior Vice President, General Counsel and Secretary</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vnda8-k8520exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="id0e9983aeab342bb88e351337ec05881_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 99.1</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><img alt="vandaq32019earningscai1.jpg" src="vandaq32019earningscai1.jpg" style="height:88px;width:264px;"></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:-18pt;padding-left:27pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Q2 2020 Total net product sales reached a new record of $62.2 million, a 7% increase as compared to Q1 2020  </font></div><div style="text-indent:-18pt;padding-left:27pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Q2 2020 HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> net product sales reached a new record of $41.6 million, an 18% increase as compared to Q1 2020</font></div><div style="text-indent:-18pt;padding-left:27pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">The HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> SMS marketing authorization applications were accepted for priority review by the FDA</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">WASHINGTON</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; August&#160;5, 2020 &#8211; Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq&#58; VNDA) today announced financial and operational results for the second quarter ended June 30, 2020.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8220;We are very proud of the achievements of our team, especially the record commercial performance, even in the face of the challenges presented by the pandemic. We are also very excited with the progress of the HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> SMS applications as we get closer to providing a therapeutic solution to patients with SMS,&#8221; said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO.</font></div><div style="margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Key Financial and Corporate Highlights</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:-18pt;padding-left:27pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Total revenues from HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and Fanapt</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> were $62.2 million in the second quarter of 2020, a 5% increase compared to $59.1 million in the second quarter of 2019.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:-18pt;padding-left:27pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> net product sales were $41.6 million in the second quarter of 2020, a 10% increase compared to $37.8 million in the second quarter of 2019.</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:27pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Fanapt</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> net product sales were $20.6 million in the second quarter of 2020, a 3% decrease compared to $21.2 million in the second quarter of 2019.</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:27pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Cash, cash equivalents and marketable securities (Cash) were $339.8 million as of June 30, 2020, representing an increase to Cash of $47.2 million compared to June 30, 2019.</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:27pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Net income was $8.7 million in the second quarter of 2020, compared to net income of $11.5 million in the second quarter of 2019.</font></div><div style="margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Key Product and Pipeline Highlights</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Products</font></div><div style="text-align:justify;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Vanda is encouraged by its record commercial performance during the second quarter of 2020. Vanda continues to implement marketing and sales strategies aimed at supporting continued growth and minimizing the impact of disruptions caused by the COVID-19 pandemic, including the launch of a Fanapt</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for schizophrenia direct-to-consumer campaign at the end of the second quarter of 2020.</font></div><div style="margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Pipeline</font></div><div style="text-align:justify;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The COVID-19 pandemic has impacted clinical research globally, including Vanda&#8217;s previously reported clinical trials. The tradipitant gastroparesis and motion sickness programs have resumed, while recruitment for the tradipitant atopic dermatitis program, as well as the HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> delayed sleep phase disorder study and Fanapt</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> bipolar disorder and long acting injectable studies, is currently on hold. </font></div><div style="text-align:justify;margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;text-decoration: underline;">Tradipitant</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt;">An Individual Patient Expanded Access protocol (VP-VLY-686-3303) for tradipitant in gastroparesis was approved by the U.S. Food and Drug Administration (FDA) and the patient was enrolled in July 2020. Under this protocol, this patient will receive tradipitant treatment for a period of up to six months, which may be extended upon review by the FDA.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:right;margin-top:6pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The gastroparesis Phase III clinical study (VP-VLY-686-3301) resumed recruitment. Enrollment in this 200-person study is expected to be completed in the first half of 2021 with a New Drug Application (NDA) filing projected for later that year. </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The protocol for the pivotal Phase III motion sickness study was discussed with the FDA at the end of Phase II meeting, and the FDA agrees with the adequacy of the program design to support an application. Preparations for this study have begun with the boat trip portion of the study expected to commence as soon as local restrictions are lifted.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Patient enrollment in the Phase III clinical study (ODYSSEY VLY-686-3501) of tradipitant in COVID-19 Acute Respiratory Distress Syndrome (ARDS) is ongoing and an interim analysis will be conducted to determine next steps.</font></div><div style="text-align:justify;margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;text-decoration: underline;">HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;vertical-align:top;">&#174; </sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">(tasimelteon)</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The Smith-Magenis Syndrome (SMS) marketing authorization applications were accepted by the FDA for priority review with a Prescription Drug User Fee Act (PDUFA-VI) target action date of December 1, 2020.</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">1</sup></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt;">The FDA appeals process related to the sNDA for HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> for the treatment of jet lag disorder is ongoing.</font></div><div style="margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Key Publications</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The article &#8220;Efficacy and Safety of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial&#8221; was accepted for publication in the July 2020 issue of Gastroenterology.</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">2</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8226;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.73pt;">The article &#34;Efficacy of Tasimelteon (HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) in the Treatment of Jet Lag Disorder Evaluated in an 8-h Phase Advance Model&#59; a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial&#8221; was published in the July 2020 issue of Frontiers in Neurology.</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">3</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div style="margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">GAAP Financial Results</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net income was $8.7 million in the second quarter of 2020, compared to net income of $11.5 million in the second quarter of 2019. Diluted net income per share was $0.16 in the second quarter of 2020, compared to diluted net income per share of $0.21 in the second quarter of 2019.</font></div><div style="margin-top:18pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2020 Financial Guidance</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Vanda will continue to assess the impact of the evolving pandemic on its business and operations and will provide future updates to its financial guidance as necessary. The financial guidance previously communicated by Vanda is shown below. In addition, Vanda provides an update to Year-end 2020 Cash.</font></div><div><font><br></font></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:47.633%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:47.635%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Full Year 2020</font></div><div style="padding-left:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Financial Objectives</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Full Year 2020</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Guidance</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:9pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$240 to $260 million</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> net product sales</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$155 to $165 million</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Fanapt</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> net product sales</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$85 to $95 million</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Year-end 2020 Cash</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Greater than $340 million as compared to prior guidance of greater than $320 million</font></td></tr></table></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Conference Call</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Vanda has scheduled a conference call for today, Wednesday, August&#160;5, 2020, at 4&#58;30 PM ET. During the call, Vanda&#8217;s management will discuss the second quarter 2020 financial results and other corporate activities. Investors can call 1-888-771-4371 (domestic) or 1-847-585-4405 (international) and use passcode 49854840. </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The conference call will be broadcast simultaneously on Vanda&#8217;s website, www.vandapharma.com. Investors should click on the Investors tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda&#8217;s website for a period of 30 days.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:right;margin-top:6pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">References&#58;</font></div><div style="text-align:justify;margin-top:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">1</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Refer to Company press release titled &#8220;FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (tasimelteon) in the Treatment of Smith-Magenis Syndrome&#8221; issued on August 3, 2020. https&#58;&#47;&#47;vandapharmaceuticalsinc.gcs-web.com&#47;node&#47;14226&#47;pdf</font></div><div style="text-align:justify;margin-top:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">2</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Carlin, J. L., Lieberman, V. R., Dahal, A., Keefe, M. S., Xiao, C., Birznieks, G., Abell, T. L., Lembo, A., Parkman, H., &#38; Polymeropoulos, M. H. (2020). Efficacy and safety of tradipitant in patients with diabetic and idiopathic gastroparesis in a randomized, placebo-controlled trial. Gastroenterology. Advance online publication. https&#58;&#47;&#47;doi.org&#47;10.1053&#47;j.gastro.2020.07.029</font></div><div style="text-align:justify;margin-top:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">3</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Polymeropoulos, C. M., Mohrman, M. A., Keefe, M. S., Brzezynski, J. L., Wang, J., Prokosch, L. S., Polymeropoulos, V. M., Xiao, C., Birznieks, G., &#38; Polymeropoulos, M. H. (2020). Efficacy of tasimelteon (Hetlioz&#174;) in the treatment of jet lag disorder evaluated in an 8-h phase advance model&#59; a multicenter, randomized, double-blind, placebo-controlled trial. Frontiers in Neurology, 11, 611. https&#58;&#47;&#47;doi.org&#47;10.3389&#47;fneur.2020.00611</font></div><div style="margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">About Vanda Pharmaceuticals Inc.</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter &#64;vandapharma.</font></div><div style="margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</font></div><div style="text-align:justify;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Various statements in this press release, including, but not limited to, the guidance provided under &#8220;2020 Financial Guidance&#8221; above and statements regarding Vanda&#8217;s ability to make HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> available to patients with SMS, Vanda's marketing and sales strategies, the Individual Patient Expanded Access protocol for tradipitant, recruitment for the gastroparesis, motion sickness and ODYSSEY studies and clinical development and regulatory timelines for tradipitant and HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> are &#8220;forward-looking statements&#8221; under the securities laws. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda&#8217;s forward-looking statements include, among others, Vanda's assumptions regarding its ability to continue to grow its business in the U.S.&#59; Vanda&#8217;s ability to minimize the disruption caused by, and maintain business continuity during, the global COVID-19 pandemic and related market volatility&#59; the duration and severity of the global COVID-19 pandemic, including prevailing economic conditions and general uncertainties relating thereto that may be unknown and unforeseeable&#59; Vanda&#8217;s ability to enroll patients in and complete its gastroparesis, motion sickness and ODYSSEY studies&#59; Vanda's ability to complete the clinical development and obtain regulatory approval for tradipitant in the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 ARDS&#59; Vanda&#8217;s ability to successfully resume the clinical programs that are currently on hold and the FDA&#8217;s ability to complete its review of the HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> applications for the treatment of SMS on time and make the determination that HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is safe and effective in the treatment of SMS in adults and children. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda&#8217;s business and market, particularly those identified in the &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;, &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of Vanda&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as updated by Vanda&#8217;s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">www.sec.gov</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:right;margin-top:6pt;"><font><br></font></div></div></div><div id="id0e9983aeab342bb88e351337ec05881_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VANDA PHARMACEUTICALS INC.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(in thousands, except for share and per share amounts)</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(unaudited)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:41.088%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.679%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30<br>2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30<br>2019</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30<br>2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30<br>2019</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:20.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">HETLIOZ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> net product sales</font></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,561&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,835&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,897&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66,792&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:20.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Fanapt</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> net product sales</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,646&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,225&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,310&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,981&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,207&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,060&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">120,207&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,773&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods sold excluding amortization</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,847&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,368&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,054&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,481&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,903&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,950&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,430&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,228&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,917&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,468&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,938&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,497&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible asset amortization</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">369&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">379&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">739&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">759&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,036&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,165&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111,161&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98,965&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income from operations</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,171&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,895&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,046&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,808&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,918&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,649&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,284&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,134&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before income taxes</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,089&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,544&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,330&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,942&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for income taxes</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,375&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,130&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,714&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,526&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,200&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,914&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><br>Net income per share, basic</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.16&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.22&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.17&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.21&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income per share, diluted</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.16&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.21&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.17&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.20&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><br>Weighted average shares outstanding, basic</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,501,308&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,101,499&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,153,812&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52,928,101&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares outstanding, diluted</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,081,397&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,579,982&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,975,771&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,932,932&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:right;margin-top:6pt;"><font><br></font></div></div></div><div id="id0e9983aeab342bb88e351337ec05881_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">VANDA PHARMACEUTICALS INC.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(in thousands)</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(unaudited)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:67.941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.662%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.664%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,305&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,072&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244,544&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">267,057&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,587&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,367&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,384&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,140&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,041&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,500&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">380,861&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">354,136&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,744&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,864&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,601&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,180&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,298&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,037&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,558&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,680&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current inventory and other</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,569&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,851&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">506,631&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">483,748&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued liabilities</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,398&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,590&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product revenue allowances</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,194&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,915&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,592&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,505&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease non-current liabilities</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,720&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,455&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current liabilities</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,735&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">843&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75,047&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,803&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:20.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Additional paid-in capital</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">642,398&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">631,307&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">596&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">249&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(211,465)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(220,665)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">431,584&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">410,945&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders&#8217; equity</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">506,631&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">483,748&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:right;margin-top:6pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Corporate Contact&#58; </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AJ Jones II</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Chief Corporate Affairs and Communications Officer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Vanda Pharmaceuticals Inc.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">202-734-3400</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">pr&#64;vandapharma.com</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Elizabeth Van Every</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Head of Corporate Affairs</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Vanda Pharmaceuticals Inc.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">202-734-3400</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">pr&#64;vandapharma.com</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">SOURCE Vanda Pharmaceuticals Inc.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:right;margin-top:6pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>vnda-20200805.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:8dc27823-325f-4e18-a8bf-4ae4d4682f1f,g:d7a0f35e-3370-4959-8359-07fbdf7e30e6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vnda="http://www.vandapharmaceuticals.com/20200805" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vandapharmaceuticals.com/20200805">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20200805_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20200805_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20200805_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20200805_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.vandapharmaceuticals.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>vnda-20200805_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:8dc27823-325f-4e18-a8bf-4ae4d4682f1f,g:d7a0f35e-3370-4959-8359-07fbdf7e30e6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="simple" xlink:href="vnda-20200805.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>vnda-20200805_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:8dc27823-325f-4e18-a8bf-4ae4d4682f1f,g:d7a0f35e-3370-4959-8359-07fbdf7e30e6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="simple" xlink:href="vnda-20200805.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended" id="id6fb397273d44c6897289767669eda07_CoverPage"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>vnda-20200805_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:8dc27823-325f-4e18-a8bf-4ae4d4682f1f,g:d7a0f35e-3370-4959-8359-07fbdf7e30e6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_857721e6-5577-4b10-a81c-c705605014b2_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_e59512ff-f5de-4120-b135-133968eb1426_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_400682c1-ea99-44cf-a06c-501d48e4aa0e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8626c7e5-d7a0-4973-92af-36cca8b8b3b8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_2cb6f9f4-1319-4e23-9ffb-50822f859686_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ae7d5072-0d8a-4ae6-b0d3-f2915fc40640_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_af2ed654-0480-416c-83fe-cc3b18b31e6c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_a4ae66ac-b773-42ec-b871-67e18754a3b1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ccdd9cc6-cff4-45a5-9805-70cc916ffb7e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d9cef6d6-417e-4724-b8fc-8c796b2c981a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4dd7797d-5419-4250-8dc7-6eae18acd42a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_abf73239-49dd-4688-9ec6-7cc0ac26653d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8a6350ef-a9fb-4fa5-996e-2a4ff7bff2c8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7f86ee64-e78d-409b-a1f6-2ef1e6c6a2e7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_52c526de-b3bc-4cf5-a729-13736fa1d9e2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_52e7462e-244f-45d4-99b7-b5d4b72b1cc6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4a9b687b-2f83-46fc-af2c-7f8edd4c1cbe_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3d2915c5-629d-4443-96ed-2c1f2f9aa1c6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5eb4c24a-af19-4a8d-8e24-d2dcbd534e5e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_561e8698-b53a-409c-9b22-d87a0252dc3d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_e073e42d-7369-45f3-924f-75de137c4bcf_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4f7cca99-fb1d-455c-b70f-a1fb803286a2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3ec985ce-9a87-423c-ad72-05347b65fbcf_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>vnda-20200805_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:8dc27823-325f-4e18-a8bf-4ae4d4682f1f,g:d7a0f35e-3370-4959-8359-07fbdf7e30e6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="simple" xlink:href="vnda-20200805.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e6c1b3b9-ed29-494a-8314-ffa42ea71e2c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_DocumentType_e6c1b3b9-ed29-494a-8314-ffa42ea71e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d1ea15dc-040b-43d5-bd5d-0d117f535cfe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_EntityRegistrantName_d1ea15dc-040b-43d5-bd5d-0d117f535cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_974d66b5-be20-4081-b568-76f795b60920" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_974d66b5-be20-4081-b568-76f795b60920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_813725ac-0a5c-4424-9ae8-1385484522c5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_EntityFileNumber_813725ac-0a5c-4424-9ae8-1385484522c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c97757eb-3109-4d30-8bd9-5af98af76aac" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_EntityTaxIdentificationNumber_c97757eb-3109-4d30-8bd9-5af98af76aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e20ebc70-7df9-4291-bc9c-d69d6bf6d252" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_EntityAddressAddressLine1_e20ebc70-7df9-4291-bc9c-d69d6bf6d252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_804868ba-dec6-4fee-80df-e81e44f9f735" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_EntityAddressAddressLine2_804868ba-dec6-4fee-80df-e81e44f9f735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e25c8589-ee6a-458f-ac04-a1e31cf31654" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_EntityAddressCityOrTown_e25c8589-ee6a-458f-ac04-a1e31cf31654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_430bde3e-2132-4bb3-b0be-6dbf6dc40ba9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_EntityAddressStateOrProvince_430bde3e-2132-4bb3-b0be-6dbf6dc40ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_53c87983-8177-4c96-84ed-a79ae1feea40" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_EntityAddressPostalZipCode_53c87983-8177-4c96-84ed-a79ae1feea40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_de9eddd6-b7a5-4c88-bcd0-5d1bbb2b6e30" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_CityAreaCode_de9eddd6-b7a5-4c88-bcd0-5d1bbb2b6e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_855b4b4e-8c96-40ce-9d83-1dbb87daa6c5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_LocalPhoneNumber_855b4b4e-8c96-40ce-9d83-1dbb87daa6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_58e5d74e-e808-40aa-a55b-11d9b12e7d43" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_WrittenCommunications_58e5d74e-e808-40aa-a55b-11d9b12e7d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a2ae21c2-7358-4b65-bba3-efe7876504a0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_SolicitingMaterial_a2ae21c2-7358-4b65-bba3-efe7876504a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_52cb0e4f-f6fd-41aa-9a9e-5fc40f5d14cb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_PreCommencementTenderOffer_52cb0e4f-f6fd-41aa-9a9e-5fc40f5d14cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f8a9942b-f170-4705-aacf-b6a4607d0692" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f8a9942b-f170-4705-aacf-b6a4607d0692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_47ee9e96-d1ff-4236-911b-7f046dc3cc0b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_Security12bTitle_47ee9e96-d1ff-4236-911b-7f046dc3cc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_db02ecba-07e3-44ec-b7aa-6bac1262e271" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_TradingSymbol_db02ecba-07e3-44ec-b7aa-6bac1262e271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ea2de288-7f75-4f55-a517-5de24701ad5e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_SecurityExchangeName_ea2de288-7f75-4f55-a517-5de24701ad5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ce587a67-f7ef-458b-8f5e-f7aa08bb7fe1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_EntityEmergingGrowthCompany_ce587a67-f7ef-458b-8f5e-f7aa08bb7fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6cc5197d-3366-4e83-8f19-03d0c502079b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_EntityCentralIndexKey_6cc5197d-3366-4e83-8f19-03d0c502079b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_93aa2f10-6a65-4151-85f8-01fe4d0aca3d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_AmendmentFlag_93aa2f10-6a65-4151-85f8-01fe4d0aca3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6264ea4a-05db-4cae-ab5b-e7cad68aebde" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_188cd25e-5e52-4e73-81c9-bd3c53a2bd9d" xlink:to="loc_dei_DocumentPeriodEndDate_6264ea4a-05db-4cae-ab5b-e7cad68aebde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>vandaq32019earningscai1.jpg
<TEXT>
begin 644 vandaq32019earningscai1.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M^RO?-WL^7]FN]]W Z;&SMY)I#YZ8T+D"O$D"@'F:#IFYGCM;=[F7^SC0L?L
MKUJY[NW-D]Z;IW%N[,R>7*[FS>3SN08$E!592LFK)8X@WZ((6ET1J.%10
M![XM[]O-YS%O=WOVX&M[>7,DS^FJ1RY ]%%:*.   &!UCY<W$EU</<RYDD<L
M?M)KTG?93TQU[W[KW7O?NO=2J*MJL;6TF1H9GIJV@JJ>MHZB.WDIZJEE2>GF
M2X(UQ2QAA<$7'M^VN)[.XCN[9BES$ZNC#BK*0RD?,$ ]61V1PZ&C@@@_,<.J
M,/YU'65+LKYU;O[$PM"E!M3Y,[*V'\C]OPPQVC2M[ PJTF_HGE"B.2I':. S
MCR 79!(JN6<%V^G_ .[OSK#S[[0[/O\ $06>U0, ?AJJNJ<21H1U0@GBIZQW
M]Z-K6PYZFOH5TVNY0QW:?;*M)?S\9)"?2N<YZJ:]S;U%'6Z?_P )J?G14;XV
M#O'X/=@YGSY_JVCJ>P.DYJZH=ZJOZ\R.4";SVA#)426?^YVX\G!6T<*ZI&H\
MI.JA8*(6Q=]\^4Q:7D7-=FM(;@B.>@P) .Q_]NH*L>%4'FW697W<.=VO;";D
MF_>L]J#+;$G)B+?J1Y_WV[!E''2[?A3K:I]X^=91]!1WG4=R4?4'8==\>X-C
M5O=>/VQD,CUOC.RL?E\EL?-;FH$6LI,!N"#!;CVEE(*;/QP/11U4=?"**>=*
MAUFCB:&0QVE=L;<H4WDRC:FD E,1 D53@LNI7%5^*A4Z@"HH34%6]MO";1</
MR^(#O2Q$PB8,8V<9"N%>-@'II#!AI)#$$ J=2KXV?\*5^_J'O/;77GS/Z>ZE
MV_UTVX8MD;]W#U_MO?NSM^]>Y1*W^#9#<FX<1NG?6[<?D:; 9!"^5QT-'05,
M<:2F&\D:4[Y%[Y[&;.^TO>\KW-R][H\2-9&C>.04U!5*1H06'P,2P)I7!U#%
M+ES[Q^_)OD>W\Y6=I'M_B>'*\22QRQ-727=7ED!"'XT"J0*Z<@*=R.BK:/(T
M=)D,?5TU?05]-!6T-=13Q55'6T=5$L]-5TE3 SPU%-40NKQR(Q5U(()!]XRL
MK(Q1P0X-"#@@CB"/(CK,!'21!)&0T; $$&H(.001Q!\CU)]UZMU[W[KW7O?N
MO=%-^;GR[Z^^#OQPWY\ANPXSDJ7;,%/C=K;3IZR.AR6^M\YEGIML[0QE0\-4
M8),C4JTM3.L,WV>/IZBJ,;I RD1<J\MWG-F]P[+9=K2$EW(J(XURSD8X# %1
MJ8JM17H*\Z<VV')/+L_,&X#4L0 1 :&65L)&IS2IR30Z4#-0A3UKC?!K^=I_
M,>^>GR[Z^Z-Z]ZI^,FV-FY+*Y'/;\R3[&[2STFS.I\9/3RY[/9K+?Z7*&.MS
M>-HGCH\:T4..IJ[,UM/%+&L<MHYMYL]J^2.4.6YMVO;B_DNE4+&/$B77,?A5
M1X)HI/<U2Q5%8@U&<=^2/>CW$YZYMM]DV^UVR*S9BTI\*=O#@4C4S-XXJP%%
M2@0-(R@@ XVCN^N\.O/C;T[V%WEVKF$P>P^MMMUNX\[5WB-54BG58J##8F"6
M6%:[/;@R<T-#04P8-4UE1%$#=A[@+:-JO=\W.':=O77=SN%4>0KQ8^BJ*LQ\
ME!/63F^[WM_+FT7&][H^BQMHR['S-."J,59VHJCS8@>?6D/G_P#A3%\^ZS.Y
MJKV[M+X]87;]5ELC48+#5VQ=T9BMQ.'GK)I<9C*S+C?>/&5JJ"B9(I*D4\'G
M="_C35I&54/L5R>L*+/)>M,% 9A(B@M3) \,T!.0*FG"IZPKG^\ESX\[O;Q;
M>EN7)53$[%5)[5+>*-1 H":"O&@X=;27\IW^8ABOYA_QLI]ZYI,)A.[^OJ^/
M:7=6T,+JIZ&DS,D<M1@=W8+'U-;6Y"GVKO3%Q&6G\KMX:ZGK*57D%-Y7@'W$
MY+DY+WPVL6M]JF&N!VR2O!D8@ :T.#3BI5J#509.^U?N#%[@\N"]FT)O5NWA
MW$:X ;BLB@DD)(N17@P=*G34VA^P#U)O7O?NO=:MO\XO^<7\M?@E\M<=TETE
MCNH:K9M5U#L[?$LN^-G9O/9K^-9[-[NQ]<JUV/W=@X!1"#!P^./PEE8L2QN
M)^]L_;/ESF[EQMUW5KD70N7C_3=572JH1@HV>X^?6,7N][O<U\C<UKLNRK:&
MS-I')^I&S-J9I <B112BB@IZYZ)S\4O^%,W=T/;^$H?F'LCKS(]*9E?X7FLY
MU+M/-X;>.RJNHG@%+NI*'([KSM/N?#4"AQ6X^-(:MH7\M.[RQ"FJ!-S#[$[4
M=M=^6I9EW1<JLSJR.!Q2H12K'\+&HKA@ =2A#E7[R>]#=TCYO@MVV9^UF@1E
MDC)(H]"[!U'XD #4RI)&EMRC8'8&Q^U=F;<[$ZVW7@=\;%W=C8LOMK=>V<E3
M9;"9G'3,Z"HHJZDDDAD\<T;Q2I</#,CQNJNC*,9+RSN]ONGLKZ-XKN-J,C A
ME/H0?VCU&1CK,&PO[+=+./<-NECGL95U(Z$,K#U!'[#Y@@@Y'2P]INE?7O?N
MO=>]^Z]UK&?SI/YO'RL^ ?RDV%T[T9C^IJO:6Y>@MK=EY&3?FT,SN#+KN+,=
MB=I[6JTIJS';LP,$6-&,V;2%(C"SK*9&+D,%6>/:[VWY>YPV";<]V:Y%S'>/
M$/#=572L<3BH*-FKG->%,=8T^\GNUS3R'S/!L^QK:&TDL$F/BQL[:VEG0T(D
M44I&N*<:YZN7_EQ?(3?GRK^%'0WR![.AP$&^^R<!N')[AAVMCJG%8!*C%[XW
M1MZF&.Q]97Y2IIHS08>(L&J)"9"QN 0!&/.^S6?+W--YLU@7-I ZA=9!:AC1
MC4@ '+'R'4Q>W?,%]S3R98;_ +F(Q?7,;E] *K59'04!+$84>9SUKI_.O_A0
M1\R_C#\O._.@=@]9_&3+[.ZLWY5[7V_DMW[,[4K]S5F/IZ*AJ4FS-9ANY\!B
MZBL+U+ M!14Z6 ] ^IFOE+V;Y8W[ENSWB\GOUN;B$.P1X@H))':&@8@8\V/V
M]8\\\>_G.'+/-M_L-A;;8]G:SE$,D<Y<@ 'N*W"J3GR4#Y=%,_Z"@/GU_P ^
MB^('_H ]S_\ V_\ V(O]83D__E)W+_G)!_VS]!7_ ()GGS_E$VC_ )Q7'_;5
MU[_H* ^?7_/HOB!_Z /<_P#]O_W[_6$Y/_Y2=R_YR0?]L_7O^"9Y\_Y1-H_Y
MQ7'_ &U=>_Z"@/GU_P ^B^('_H ]S_\ V_\ W[_6$Y/_ .4G<O\ G)!_VS]>
M_P""9Y\_Y1-H_P"<5Q_VU=9J?_A4#\\EJ(&J^G?B--2K-$U3#3[([DI:B6G#
MJ9HH*F3O>KCIYI([A7:*548@E& L=-["<HT.FYW(-3%9(3_+Z<5_:/MZVOWF
M>>@P+V>TE:YI'< T^1^I-/MH?L/1KNEO^%35><K04'R(^*]#_!IYT7);IZ9W
MK4)D<;364/)1[$WK234^7EO<A7W#1 "PN3S[#VZ?=_3PR^R[@?% PDZ"A/SD
M0X_YQMT*MF^\_)XJQ\P[6O@DY>WD-0/E%("&_P"<J];._P 7?EKT%\R>LZ3M
M?X^;^QN]MLR3"AR](@>@W+M+-",2R[?WAMNK$>4V]F(T.M4G01U$)6:G>:!T
ME:!M_P"7-XY8OSMV\PM%/2H/%77^)&&&7[.!P0"".LE^6.:]AYPVT;KL$ZSV
MU:,.#QM_!(A[D;Y$4(HRDJ029#V1]"+KWOW7NBQ?,;Y4=??"_P".W8WR%[&D
M6;%;*Q+?P3;\=5'29'>F\<C>DVKLS$R.DQ6MS^6=(WE$<@I*82U+J8H9"#[E
MGE^\YHWJ#9;'$DK=S4J$09=S\E&:5%311DCH-<W\T6')O+UQS!N.8H4[4K0R
M2'"1KQRS4%:'2*L113UI:2?\*6_YB+2.T>"^.$:,[,D?^C;=3^-"Q*IK;L:[
M:1Q<\GWE$/8ODNF7OJ_\U4_ZU=8:G[R'N"341[<!_P T7_ZW=;?G\N;YN;2^
M?/Q>V5W?A%H,7O!$.U>V]FT<P<[-[*PT%.,[011//45$>$S$<T63Q32.\CXV
MLA$A\RRJN-G.W*MSR?O\NU2U:V^.%S^.)B=)\AJ7*O3\2FF*=9;^WG.MISWR
MQ#O<.E;OX)XP?[.90-0XDZ6PZ5-=#"N:@'L]A+H<=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T'':W7%%VSLVLV'E\MD\3@,
MU5T!W V&:GAR>0Q=!4ID/X73UE1#4I0I65U+ )I!&[-3B2,6UZE"7._*5MSS
MR_)RS?SS0;7<.GC^%I$CQHP?PU=@P0.ZIK;224#(*:M00[C8IN5J;.5F6%R-
M6FE2 :T!-:5(%<<*CSZJG[DG_E&]*YRNZ_[0^1/777^^<94+C\OA!W&,EN_
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M[^MG,O[GV]Z[%MS,BT.))N$LGH0M/#C.<!F4TDZV6/Y%W\OA/AG\7:3L3?\
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MH>NC=K=6]]:QWMFZR6DR*Z.IJK(P#*P/F""".E![9Z?ZT%/^%+7_ &\4PO\
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M9]BN7"U[8KZ-HB1Z)<Q*T4I/E^G&OJW4BV.U;'S%$;GE'<[6]C J4UC6H_I
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MTY*13T'!@/TW/^F4:"3@:4'%NLP?NV\Z>-:S\CWS_J0UGMJGBC']:,?Z5B)
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M6+41%_LIE$J^T_)G]:-_%W>I79K(AY*C#O\ Z''\P2-3C^%=)IJ'4*^]W/\
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M@:>?_"EK_MXIA?\ Q7#K3_WJ>Q_>2OL7_P J4_\ SW2_\<BZQ$^\A_T\)/\
MI70_\?FZVS/Y0O\ V[2^'/\ XB#'?^[;+^\=O<G_ )7K<_\ GI/^!>LJ_:7_
M *=OL_\ SR#_ (\W5C_L$=2+U47_ #2/Y3'4O\P_93[@Q@Q/7/R6VKC*B/8W
M:L./1(=Q004TK46Q>S31P-6YG:,U45^WJ@LU=A79I:8/&]12U,C\@>XNX\EW
M7@OJGV*1OU(J_#G,D5<*].(PK\&H0K+$WN=[4[5[@V7U$>BWYDB4^%/3XP!B
M*:@JT9/!LM&:E:@LC:1_5O;GS1_D_?+#,TL%'D^M^S-GUM-B^Q.LMS/4UVP>
MR]M?NS45+G:3&5\..W9M?)TE4]1BLI15'D@,HGHZB.2Y]Y4[AMO*_N5RZK$K
M/82@F.5:"2)O,J2*HX(HZ,,THP(ZPMVO=N<O:/FIT4-;;E"P66%ZF*9/(,%(
M$B,#5'4U%=2,#UOV?R__ .8CT5_,*ZICWUU?7_P+>^!AHZ;L[J3-UM*^[M@Y
MJ>%"[,D?B.=VE7SZ_P"&YB&)(*Q%*2)!51STT.'_ #CR7NW)FX_27XUVKDF*
M90=$B_\ /KC\2$U'D2I#'/#D+W!V/W VKZ[;&T7J ":!B/$B8_\ 'HR?@D H
MPP0K!E74\_X5 ?\ 9?747_BH&P?_ '\_?_O(?V$_Y4^Y_P"EE)_U8M^L5OO,
M_P#*^6G_ $J(O^TBZZV;/Y)O_;KCXC?^&AO+_P!^KOWW!'NG_P K_N7_ #53
M_JU'UDI[+_\ 3L=I_P":,G_5^7K1T_F\_P#;RWYC?^)@R7_NJQ/O*_VW_P"5
M%VS_ )YA_A/6$WNU_P!/(WC_ )ZS_P =7KZ/7QZ_YD%T=_XA_K3_ -XO"^\(
M]Z_Y+%W_ ,],O_'VZZ)<O_\ )!LO^>2'_JVO0P>RSHWZ][]U[KWOW7NN$DD<
M,<DTTB111(TDLLC*D<<:*6>21V(5$102238#WL DT''K1( J< =?*8Z;_P!_
M5\NNJ_X#_E_]Y/D=L?\ @O\ RB_>_P 8[-Q?\._X&_;_ &_W'W"?YWQZ+^K3
M8VZ$[G_B_+=QXV-%C)J\Z:8C7A6M*>77+79_\:YMM? [O$W&/3Y5U3+3C2E:
M^=/GU]17O'N?8'QVZB[![N[2S,>!V#UIMJOW/N+(/9IFIZ15CI,;CX"RM6YG
M-Y&:&BH:9/W*JMJ(H4!=U'O 7:=KO-ZW*':MO77>3R!5'S/$GT515F/DH)/#
MKIOO>\V'+VTW&];HXCL+:,NY^0X #S9C15'%F( R>OFR]H[Q^3'\W3YS9G+[
M7VU6;K[4[CS=;1; V%!E*>+$;'V#MJ@K:S#;;BRV4EH,3B<#M+;5$\U;62FF
MBJ:LU%5(//4OJSBV^VV+VWY36.XD$>WVR R24-9)&(#-05)9V-%45(%%&%ZY
MR[G><R>[/.[RVT9EW2\<B*+4-,42 E4U-156- 2S&@+:F/<QJ>3;?\DG^<WL
MW&_P;:&W\CM3$">6J_A6V_DQLW!8W[J<()ZG['%[\I:7SS"-=;Z=3:1<\>PI
M/[J>V%T_BW+K))2E6M78T]*F,GH;VWLM[Q6<?@VD;10UKI2\C45/$T64"O3_
M /\ #.G\\3_CKO#_ -*QV]_]L3VS_KF>U/\ PK_LD;_K7T__ *T/O9ZS?]ER
M?];>FG._R5?YTVZ,55X+<V*S6XL'7B):[#9WY/[2R^*K5@GBJH%J\=D-_5%)
M4B&I@21 Z-ID16'(!]N1>Z7M=;R":!E24<&6U<$>6"(P1C'34_LS[RW41@N5
M>2!N*M>QLIH:BH,I!R ?MZKSS6S/EK_*A^7>P\KN_;T_67>75==MWL/ 0G)T
M>9V_N7;N5BFBFIX\SMS(3XW<6T=T8TUV'RD=/4FZFKI)"DJ.JC.*ZY<]P^6Y
MH[9Q/M-P&C;!5E8>>EA570Z72H_A85!'4?S6?-?M7S;!+=QFVWNU9)4[@R.C
M5J-2$AXW&J-P#_&AH0:?1]^(WR=Z_P#F+\>NM?D+UM4+_ M^X.*IR&&DJ(Y\
MCM'=-$QH=U;-S.@)IR>V\W!-3L^E4J(E2HBU0S1NV$?,>PWG+.]3[+?#]:%Z
M!O)T.4=?DRT/R-0<@]=$N4^9MOYOY?MN8-M/Z$Z5*UJ8W&'C;^DC CYBC#M(
M/1D?9'T(^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7V_X4
M9_%?<G?'PNPO;.RL?59?<7QCW=5[YS.,HXIJFIGZQW)C4PN_*ZFI8%9I)-O5
M-)B\I4.?1!C**KD/"^YD]D^8(-HYH;;KI@L%_&(U)P/%4ZHP3_2!=!ZLRCJ
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M%\].'8?Q:/-3U)'W=.0/IX&Y\W-/UI0T=H",A/ADF%>!?,:'CI$G%7!Z2O\
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MC);34Z02305-!0$GCT8OV2="'KWOW7NO>_=>Z++\JOA]\>_FCUQ+UA\ANO\
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MZ57B: DGT  !))(  ))IUK==VV[8["3=-VF2"PB +.W 5( &*DDD@  $DD
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M,Y\(_P#LHS^9Y_XM_M3_ .!>Z']D/-7_ "1-A_Z5K_\ :5<=";DO_E8>9O\
MI;I_VA6O2*_EXTL,7PV[Z6EIHHWJ?DG\^&D6GA5&GF7Y ]L4L3.(U!ED6G@C
MC4FY"(JC@ >U7.C$\S6>HX%CM_\ VCPG_9Z1>WR <GWX4"IW+=.'G_C4X_P
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M_P !SVW[0<N_\JGS#_SS6G_:;#T9<U?\KORM_P ]=[_W;Y^O?S9O^R&M^?\
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(7NO>_=>Z_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>vnda-20200805_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vnda-20200805.xsd" xlink:type="simple"/>
    <context id="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV80L2ZyYWc6YmM1MTk2MDMxMWYwNDgyYmJkNDY1MDk1NjZhZTY0MTMvdGFibGU6OTFjYzc3NjZiNGEyNGEyYzkzMTU5ZmRlOGFkM2I2NWEvdGFibGVyYW5nZTo5MWNjNzc2NmI0YTI0YTJjOTMxNTlmZGU4YWQzYjY1YV8yLTEtMS0xLTA_5ed66de5-734d-4c6f-a887-ad503d8cb1ce">0001347178</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV80L2ZyYWc6YmM1MTk2MDMxMWYwNDgyYmJkNDY1MDk1NjZhZTY0MTMvdGFibGU6OTFjYzc3NjZiNGEyNGEyYzkzMTU5ZmRlOGFkM2I2NWEvdGFibGVyYW5nZTo5MWNjNzc2NmI0YTI0YTJjOTMxNTlmZGU4YWQzYjY1YV8zLTEtMS0xLTA_42375de3-0d11-46bd-8ff6-9dc5b428b1e4">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzc1_560fd78e-551d-466f-9b60-21af5325c17e">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8yMTk5MDIzMjU2OTM1_4eadf342-5607-41c1-a01c-7d0f46abe156">2020-08-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzgw_ece8370b-e912-4159-a428-cc2deb9788d1">VANDA PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityFileNumber
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6MjE4MWVhYTFjY2QzNDJhODk0NzY4ZmNkOGZjZjcyNTAvdGFibGVyYW5nZToyMTgxZWFhMWNjZDM0MmE4OTQ3NjhmY2Q4ZmNmNzI1MF8wLTAtMS0xLTA_c0871f35-9151-4059-bdf9-d9eb24fce35a">001-34186</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6MjE4MWVhYTFjY2QzNDJhODk0NzY4ZmNkOGZjZjcyNTAvdGFibGVyYW5nZToyMTgxZWFhMWNjZDM0MmE4OTQ3NjhmY2Q4ZmNmNzI1MF8wLTItMS0xLTcx_de2729bd-cdea-4b9d-8243-46909227392b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6MjE4MWVhYTFjY2QzNDJhODk0NzY4ZmNkOGZjZjcyNTAvdGFibGVyYW5nZToyMTgxZWFhMWNjZDM0MmE4OTQ3NjhmY2Q4ZmNmNzI1MF8wLTItMS0xLTA_f4a3b610-f688-40cf-aa71-1617dcde0a59">03-0491827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzc3_bd8a575b-8e3a-4d68-a025-59d915ede71a">2200 Pennsylvania Avenue NW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzcy_ca311536-5ac5-4226-8f17-1fcff38de8d3">Suite 300E</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzcz_8ce5c6af-a4d3-4176-993b-0145ddb03aa9">Washington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzc0_4ae81f84-3067-4c76-a8e6-07bd2bfda3e8">DC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF80NDA_d7b89baf-9168-40a2-9e60-d8fdcd37241d">20037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF81NTA_0a7ea9f0-29b9-4695-8694-9c0a62b93d43">202</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzc4_9f60cab1-9fd8-4a25-86a3-b630b326ca1f">734-3400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6YTJhMGI2ZjA5NDcyNDYwYjgyODNiMDE2NDMyNjViNWMvdGFibGVyYW5nZTphMmEwYjZmMDk0NzI0NjBiODI4M2IwMTY0MzI2NWI1Y18wLTAtMS0xLTA_5c02c64b-07ed-4b04-88c1-97c4a1b70e12">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6YTJhMGI2ZjA5NDcyNDYwYjgyODNiMDE2NDMyNjViNWMvdGFibGVyYW5nZTphMmEwYjZmMDk0NzI0NjBiODI4M2IwMTY0MzI2NWI1Y18yLTAtMS0xLTA_9449501b-3a6a-4ace-ae28-3811bac32f9d">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6YTJhMGI2ZjA5NDcyNDYwYjgyODNiMDE2NDMyNjViNWMvdGFibGVyYW5nZTphMmEwYjZmMDk0NzI0NjBiODI4M2IwMTY0MzI2NWI1Y180LTAtMS0xLTA_96cdc727-030b-42ec-a025-fc73a04079b9">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6YTJhMGI2ZjA5NDcyNDYwYjgyODNiMDE2NDMyNjViNWMvdGFibGVyYW5nZTphMmEwYjZmMDk0NzI0NjBiODI4M2IwMTY0MzI2NWI1Y182LTAtMS0xLTA_84b21cb3-186d-4a4b-8d39-db6b4b125335">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6YmVjYzZmMjMyMWVhNDI0OWJjMzE5ZjY0YTIyNzllOWMvdGFibGVyYW5nZTpiZWNjNmYyMzIxZWE0MjQ5YmMzMTlmNjRhMjI3OWU5Y18xLTAtMS0xLTA_f1a2599b-a1da-49e8-8eba-bd33d3711d5b">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6YmVjYzZmMjMyMWVhNDI0OWJjMzE5ZjY0YTIyNzllOWMvdGFibGVyYW5nZTpiZWNjNmYyMzIxZWE0MjQ5YmMzMTlmNjRhMjI3OWU5Y18xLTEtMS0xLTA_fcd52ec1-11a3-4808-8755-d1f9d3ab3137">VNDA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGFibGU6YmVjYzZmMjMyMWVhNDI0OWJjMzE5ZjY0YTIyNzllOWMvdGFibGVyYW5nZTpiZWNjNmYyMzIxZWE0MjQ5YmMzMTlmNjRhMjI3OWU5Y18xLTItMS0xLTA_4f8a1079-bfe7-4e81-8b91-a7335424c688">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805"
      id="id3VybDovL2RvY3MudjEvZG9jOjVmZjIwMzdkNjcyZTRhYTY5NTNlNmEzMTY2NmEwZDE5L3NlYzo1ZmYyMDM3ZDY3MmU0YWE2OTUzZTZhMzE2NjZhMGQxOV8xL2ZyYWc6OWI0YzQyN2NhZWI4NGE2NTg3ZDVlNDcwOWQ4ZTNlYTAvdGV4dHJlZ2lvbjo5YjRjNDI3Y2FlYjg0YTY1ODdkNWU0NzA5ZDhlM2VhMF8xMzc5_b0035940-5764-4d9c-9417-81fe3af318b4">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139882704045880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Aug. 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VANDA PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">03-0491827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2200 Pennsylvania Avenue NW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300E<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Washington<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">734-3400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VNDA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001347178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  05,  2020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ," !5$'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " # @ 51O"/#Q^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2@,Q$(9?17+?G>P6BX1M+A5/"H(%Q5M(IFUPDPW)R&[?WFQLMX@^@)!+9OY\
M\PVDTT'H(>)S' )&LIAN)M?[)'38L"-1$ !)']&I5.>$S\W]$)VB?(T'"$I_
MJ -"R_D:')(RBA3,P"HL1"8[HX6.J&B(9[S1"SY\QK[ C ;LT:&G!$W= )/S
MQ'":^@ZN@!E&&%WZ+J!9B*7Z)[9T@)V34[)+:AS'>ER57-ZA@;>GQY>R;F5]
M(N4UYE?)"CH%W+#+Y-?5]G[WP&3+6U[QNXK?[IJUX/GP]]GUA]]5V W&[NT_
M-KX(R@Y^_0OY!5!+ P04    " # @ 51F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M ," !5%102+,6@0  .80   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9A=;^(X%(:O9W^%A?9B5VJ;#VBA(XJ4 MU!TW:RA6FE7>V%20Q83>RL[4#Y
M]WL<(&$TX:3=&_)YWCRVC]]CT]](]:I7C!GREB9"W[16QF2?'4='*Y92?2$S
M)N#)0JJ4&KA42T=GBM&X"$H3QW?=*R>E7+0&_>)>J 9]F9N$"Q8JHO,TI6I[
MRQ*YN6EYK<.-)[Y<&7O#&?0SNF139KYGH8(KIU2)><J$YE(0Q18WK<#[?.M?
MVH#BC6?.-OKHG-BFS*5\M1>3^*;E6B*6L,A8"0J'-1NR)+%*P/'O7K15?M,&
M'I\?U.^*QD-CYE2SH4Q>>&Q6-ZU>B\1L0?/$/,G-%[9O4 $8R407OV2S>[?3
M:9$HUT:F^V @2+G8'>G;OB.. [P3 ?X^P"^X=Q\J*$?4T$%?R0U1]FU0LR=%
M4XMH@./"CLK4*'C*(<X,AG+-% EA /J. 3U[UXGVL;>[6/]$;) O+XA[>49\
MUW=_#'< HV3Q2Q:_T&NC+'\'<VT4C-8_B&2[E&P7DIT3DB,9Y9!#ALRV66T+
M\?#>^5<$HE-"=%"5L3#<;,D36W+;,J!YI&DM#:[S'#R. A)^"9X>@N'X^VPR
M#.ZG9/(XO$ @+TO(R_= 3D0D5285M7/FC$P--8Q(188R%T9MX1C7DN/BHS%"
M>%427KV'\(XGC#SFZ9RI.A!<PW6]\W;'ZUTA/-V2I_L>GAE](Y,8<HPO>%1T
M&T*'*[KM<[=S[?7\+H+7*_%Z[\$+XE@QK<\.)^0>WB/?1.THXHH^6#T)F1!Z
MFZRIX)0$:R9R&(T7A/>ZY+W^_[RSC:SCQ16G.8?D;;LNEGV>6SFE^R' H;V"
MJ3&3&U%KGKC<"]4K+I9&"HSNR,>]#]&5,S=4<LU%5._ON.9HB*%5MN[Y'T(+
MI38T(7_Q[*2=-"A"(K:Q.>)5]<'#';X8Q #6,Z=1< &H?1A(52,\W-SO901]
M$JZDP-RM0:3;[H"]N5@Q]JJ"X.&F_:*X,4Q QZ1I+O;>IFNI<*$%333#D*H*
MX.'V/94)C[B!:4,>(+T5ITDM#Z[2R%-5  \W[%"Q\PBZA\'\VBTSF(AA#?-M
ML3@Q?KA>(UEE_A[NU3^13;3.@:P1$)=M!*S<WL/-><8-U'&Y()[_V_QW,F51
M#OFVK67"E6Q^0M&=&AF]GI&,*K*F"52E7]T+*/<D@^;J%548ME\5 1]W[9FB
ML4V_Z3:=R]KD:Q!XAC4<1E(9OH^;\Z''R/@M6E&Q9"=7E0U"C\%T%/R),1TM
MX-_E]..4J:7MI3] P:RL@V14U(YM@V!3OOF5T?NX3^_1AC 7%!CM!*;!&_G*
MZJ%P*1?2JMWI>MT>1E8YOX^;=@#S,R[FZ%U"E[4\N$!C)U66[S>LTP_;I1"\
M5<9D+&("V\KZK,*EBLWAY=DOGSZ=VATZ1[M6^P_  [5)HTG"%J#H7G3A VJW
MJ=Y=&)D5&]FY-+ M+DY7C(*=V1?@^4)*<[BP>^/RKXW!?U!+ P04    " #
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M4$L! A0#%     @ P( %4;PCP\?N    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ P( %49E<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " # @ 5144$BS%H$  #F$   &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ P( %48.II0/4 0  ,@8
M  T              ( !G0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #
M@ 51EXJ[',     3 @  "P              @ &<#@  7W)E;',O+G)E;'-0
M2P$"% ,4    " # @ 51&445]3<!   G @  #P              @ &%#P
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ P( %420>FZ*M    ^ $  !H
M             ( !Z1   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ P( %4660>9(9 0  SP,  !,              ( !SA$  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  &!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="vnda-20200805.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="vnda-20200805.htm">vnda-20200805.htm</File>
    <File>vnda-20200805.xsd</File>
    <File>vnda-20200805_cal.xml</File>
    <File>vnda-20200805_def.xml</File>
    <File>vnda-20200805_lab.xml</File>
    <File>vnda-20200805_pre.xml</File>
    <File>vnda8-k8520exhibit991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vnda-20200805.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "vnda-20200805_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vnda-20200805_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vnda-20200805.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vnda-20200805_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vnda-20200805_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "vnda-20200805.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "vnda",
   "nsuri": "http://www.vandapharmaceuticals.com/20200805",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20200805.htm",
      "contextRef": "i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.vandapharmaceuticals.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda-20200805.htm",
      "contextRef": "i77cf71f043464f4391e969d0a054aa9f_D20200805-20200805",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001347178-20-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001347178-20-000022-xbrl.zip
M4$L#!!0    ( ," !5$=1B8#W!P   O@   1    =FYD82TR,#(P,#@P-2YH
M=&WM/6MSVDJRW_=7Z++W[CI5%M8323CQ%FOL',X:G!AL+_Z2&FE&("PDCAY@
M_.MO]XQX^A$[B1/L<*IR#&@TT]/O[NF9>?^OFV$HC5F2!G'TH:26E9+TKX/W
M_R/+__WWV8E4C[U\R*),.DP8R1B5)D'6ERXI2Z\E/XF'TF6<7 =C(LO\G<-X
M-$V"7C^3-$53UAXF59MZFF5KNJQKIB\;3+5E8KOPB3"#&A5;\U5_MU>E%E%\
MW62RKEN*;#BF(]LZ_$^Q?)?Z%M,55MFE5=/W-46W:,72F$%(Q3%U5B&Z6JE4
MB$)5!X?M9S [F&&45H.;#Z5^EHVJ>WN3R:1\XR9A.4YZ>YJBZGM!% 81PRF7
M1/.5MA.=MU0=Q]F[P2Z+1E7L)'BH6P6[33,2>6S6'@:Y?J0Y/G9).F\>W&3W
MMUZ NY<E)$K].!F2#"B(LS%E19.URAS&-+AO,C"@NO??YDG;Z[,AD=<AA:'E
ME'DK;\+W<B\>?W5T6];563^4+4;GX,\Z@0?8'*BJ+C6_N8.A%=SC4]ZT&I*H
M]Z'$(OF\70(R,T(/W@]91B1\569_Y<'X0^DPCC)@7KDS'<'$//'M0REC-]D>
M)^/>P=_^]K?W69"%[& <42(CVRJV8K[?$S^^WQ-=NS&='KRGP5A*LVG(/I1H
MD(Y",JU&<<0 @."FB@U9(CX&E+*(?X3G+9"@)/#$^#?9&?,_E ++\GQ+]15#
M-RJ&;^B.RIR*0Q6BF,#+CO^E/@-E#E-)BL@0AV9!]2@"^*:',)V$A(V(LIO_
ML&E)"BAT3?6+J5N/QR?:V;BK-W,Z.!I??70&IX.+X=6@,6G>TNO6P)M>=<[Z
MW4[7;'5:86MX=-OL=#7X.[FJ'YDG>BOLWL;JU; [;=:;^E4=>AJ>*]W+(^VT
M<WY[U;GJ-V^/M-8 _G[\?'-Z82LGVM6T>^E5NL.FVNQ<:_#>3?.R.VG5>]/N
M\,_K5KVK-NO7*KYSU>DJS4YS3#\>!^['\\IIYWC0O?5T>!:T/AY-\5_W]AI@
M.C>OAF?AZ<?CZZ;6T%J71\4[%S"6&5UU8K-YV1JT;CV O:%T._COS\%IIWG3
MZH3#JX_G1O?R\VUWT%6[%_;TI'.4-=O*S4FG]L5DM%*AS)0MW:"RX55\T$:V
M)1-J*CJU/5<%<3A00$YTPU(M^_W>"CU_/'F%',';-UG5C>.0D<@G(:J#!>%K
MH(TI:N3CD/2V!/\:P6^7"6YHNF52ILM@'539J+A4MGV_(CO4,UU#LUV5&:6#
MX]I)^^@.K?=6Q3IA/DL8Z,OT'FV$6JJ:<KT*W"!QK57-0 =]**7!<!2BDN6_
M]1-DEA7%4[Y)*72QM]J'&'\Q: %#&N<)_\;M4+7@0,$4W\*!LXX8URZS;P'%
M[W[ $HD#Q.XU"H>-_ZP*R_K+![.?5GL? 7YC.OL&1BC)ZN!I'"!0:$I0%Z\_
MFX-)'V@Z>S+[/AMD;P51,ZS.T;BWI,;W0-D+C<_1^35GXXM:6GZGL!+#()+[
M#!VBJJ&5+7.4[4\"FO6KJJ+\WWZ)MSUXGXX(<)6;[$$/XK/HZ$YW"+1,PJ 7
M53W (DOVAR3IP1A9/*H:T'GQU8VS+!Y6*_ +C)$1-V2S+MPX@>G)7AR&9)2R
MZNS#_LR@">,N\Y?VP2_, H^$Q: P3 &_XY1M4^=3R !9&9WU7TRO+*:WE]&[
M#QV[K"B//%]Y>8]W+X8 6!$]'TIZ:?9&@5P=9NH2[[J7Q'E$<79Q4DUZ[HYF
MFKNS?Y)25M[M+^$P9'ZV/D6!NOT"304BH7N)QCFB\>\*_V]_1"@-HIZ,?515
M&'[V W=_^2\K4]CC"/T6FI8$@\P)^+1IBF<S:'U@>-DGPR"<5O_9"8:@MEIL
M(IW%0Q+]<S<%'PZ<O23P1<,TN&55U8:Q^=>)P+$%_7#6*'"N:IQ,YZU&YZ@N
MM3NUSE%[E7\?G>6&3ZM]='A^UN@TCMI2K567COY[^$<-;)1T>-IL-MKMQFGK
M%<Q5>]I<+TG:!];-XFA7JI</RQ"\F8;S_/G=I\.>PNDOKZXTLZPYVIM75Z@R
M0/-(:1P&]">JJE4";K)8'Y^>-?_Q=[6B[+]@<#9+FHBP\U>ZZ#<S%_WT$MSD
MV\_3EM;J7UTV#%!E6JO3@SXNPE;=FYQ>?C:N8,QNIP;N]H5!__@SO-+"L3N(
MS>[@;-"J-_2N=AQV!SUPM[OJ:1W@O3Q76K<U\ZK>#YO:1;]Y;-\T;SWUBUE1
M?&K93#9-%0*K"@16CEM19$TEOJEKIJ=:$%C9\G_N>ME"=?P2#E*>QD'25K_]
M/OKM5VFS%^#%#?=!P-LZ.VIUI+.C3Z=GG;<SKT]YDN8DRJ0LEMK,PRRIL#^J
M+L6)I)H[])WX(?;?SJRS/L/9YDF0!=#MT8W7)U&/234ODV)?4AW=>+X:1>FO
M/!3D;C(V,!6!TSYCHSC)I)W9=T:2$-"326R,2RP)?\SHNZKTHJE%"L,/H<<^
M)=,IP,"B^YR73SQE<B02*;^7%S-M=J[-9KUQVQR< TQ-]8O!"/5U0Y/!M;%D
M0_54F2BJ)UM4\8T*<9EJ5DH'M;R7IYF09F RQ/ZZA[/U'K;>PZ;$0B^^/'7&
M>D&**X19"Y[\7CH$(J'>Y OSF*U;BBLS1]5 ;YB.3 S-ECU/H\QU+-NF:NG@
MHM:JUZ1/?]3.FK7#H_-.X[!VTI8:K</R0P'2JPK-G^C,[AS=$' /D(F$L9PQ
MCT12*1TQ#U<1J!1$4I"E$C@48"N3=UM]^MOIT\U-,SJ5LF)^(^%UO:RKVA,)
MO_Y0*:N//304^QO??714K5)6S4=ZWD"0.9:-'R->,\9&.=!&-W-&+_@,?WJ^
MV!4L>P^+/4VPEC7\5W3PDW7YJ@EXXIQ^@G]Q'(0,>G=9\BI]"U$(T1P<&<W+
M"X#G>-#5/M^VZG_V3^O7X$]TC:MAZ_KTX]7@"F!NS=^9%T) G-*[N;H\[F-!
MQ%6]J32'1\9IY[/>&O2'T!>^/VS=-E3P1R8GG=J\$,)3;$"^;LJ.:JJRH8!;
MXE+?D:G#7,WP/::;!!?S55DW5+ORH!=22- ]LO%#[<TS3,HOE]1G@?R6A74I
MXX"%A%B]D;%1$H]1BE=3#D*:&Y$7)Z,XX96$;6Q]"'!GR?0PIJ\S>/C9 MXH
M!-R[^4*99FF."U2GC,B&ZU#9U@Q=-BJ.XFB:I3N:6SJHLY!,2,*V KXUQ=]G
MBCODIE%4>GE<@+=V^=EB6_OB&T1W*ZHB^Q7;!KOL^3(AEBJK%=6B(,D*,1VP
MR[JL&(YJ:]:C<OMVO-?[\EDO+3$[A_%P&*2X*T)"/U-JQ>5W6[WXQHC,W0Q<
MAXNS/DND09X$*0WX*AWFH()EEV1+_;=&_<996SH:CL)X"K1?-5]WQ?T[JCCY
M.N&&9U]?W$.H49JP-"W^G  $ZJOT#KZK-DK_XE*;F);IRC;3P3&G%5LFBF;*
MID,A&&>462J$WAI@4?K$HBB=AF,2!42JC5F4@Q6Z_(XE@2T+KK.@]ONQX/2+
M1W15-?6*;!+/E U-J\BVKUJRZGN^K]N4V50O';3S $RCKBCW[(79<MSS..X0
M/IXFG7@2_7[\=OO%]ICI50C$,@;594.U*K+CZ*ZLJ(9)J:OH@,[E(O1U?MO]
M\>4P#]")NX.GR:<D'@=\+^SO1BSEBT&8K?JV(>M*Q9(-#XA%;%:1%<NEFNM3
MHC.[=% _O%O8\I-H]"E.,Q)>!:-7FQ;\9@HIK7KM"[5<VW%!FARU@CD"HLD.
MJR@RM7WJ4=W2#)6" Z$H^L/I@8U5W$^L7-DI> %CM%$"HAJ,2"BQ&^;E63#&
M\@'PXV$X$E'I-A@!,U+V#94"K\5W7Y1*_./OMJ9:^ZF4L9"-^G'$I(@GXG8Q
ME@US#,<DDC#"45*5=EY0:M'HU6"HWT].U5:G]D4A%@,D*;+FN [FW4W9KCB&
M['@*J6BNHU-#1SG5UJ7TW4NJTI,88O9/R!BO.$'[72;.^.+X%<4CKBH[/@4-
M2C2D#-%EMZ(KKJY5/*+ZI0-+!QMH*'<J..^HD0W1#<;]NJ'8[/20[OOM-@QO
MEX*_FA=KQ9E4&XU"F J0=$/7%'X <G])SO$X3D"/2"U>Y9A(Q=?"GP$K[4N'
M?*L$E=H8@D@G),V*C0,_)!^YK7[<[.K'3;4FJLEW:?69=RWA[AXR&B4Q^-ZX
M?N+&-Y++PGB"[(L/D:N%X;'E_TA^$*+;&:3@@V8LHL#;62REP3 /,Q*Q.$_#
MJ922+$C]*7^]>"%V >UDMA:##Y)%33"@!.2&1-/9,Q^X-9[@>UAD$N#"72KM
MI(Q)'UG$$H@/&A&\FXO%G5I9*PN8WU4WQ*)7WI1!?[1$4RM;VHN4=SIF6;&>
M6D3[*XS9?7KEAU>4&.L,6 ,Y#:7S*,"H3VJV-[*D9+U@#$_ <@D(=0;Z93F&
MN4R"#/0(+M#G4;%>E[[*0$94FG0[?T(_#>UJ4#.AS;15[TX@D)F>UEM!LP[O
MUYO3UN B:%TVURI-1OTFP-P=7 V;O#*EH;0&_PY.ZPVCJ<%<\<BM6SQ"JZ%V
MU=4*4--3-*]BN+)B,2H;KF+(MNU!2&1Y!E%=2V&JAKK&L0QC_QO*P]Z0\+R
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M)"- )>#"-R/(C2'J,@SQ?;!9<5)@B5,7)!8S#O![3L*Y8@8YIP'6PLZW+85
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M>+!A+2+A%*PJ<O<]F1K>YM[<SFRT5"Q:\:>K"*I%$7+[V6HLKRIXCEFA07T
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MBHDG191G-(W#F(K!@$>)F[HOBJ,H!<'\^-\%WYA<M.QI[S]02P,$%     @
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MPV0).X8ZI(5&#GJG@KKG@>7?&%I=\LVF]C+_ELT3EA1)>O6G2AUY0N<SQ.)
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M4P_F2B0C2MWV17+?0&.3[.[:LL>W.S> .R[#V^6W;2_;G[5AFMD.A'5?C=?
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M95IC8C;LVHU_%5>)?F,C+<J7M#W!HM!G D8T)! CCT'*]987J@4G<>!+BQF
M:8"QB7G=5CZ!M'S3W4ABVY:[.S7#--MM6>G08YM#[]U=[[@=N*\V!U7OJ!OL
MFB2\S?N%.CI[L?DD6>WI?_;B_U!+ P04    " # @ 51CZ.BD.0&  "J,P
M%0   '9N9&$M,C R,# X,#5?<')E+GAM;-6;WV_;.!+'W_M7^+ROQYBD2)$*
MFBQRV?807'8;M%ET<2_&D!S:0F7)D)1?__V-E*1MFK2KBP5$?7%LF>;,?.=C
M<CA67O]ZO2EFEU@W>54>S,4>G\^P]%7(R]7!_,_SM\S.?SU\]>KU/QC[ZU_O
M3V>_5?YB@V4[.ZX16@RSJ[Q=SSX&;#[-8EUM9A^K^E-^"8P=]A\ZKK8W=;Y:
MMS/))?_VW7K?!B^-E0E+I(Y,H; ,K*-G@"JHU,HHXC]7^\$ CXE&EB2&,Y7I
MC-F$'KB)+D2#"<>TG[3(RT_[W8.#!F<47-GT+P_FZ[;=[B\65U=7>]>N+O:J
M>K60G">+^]'SN^'7C\9?)?UHD679HG_W\] F?VH@32L6?_U^^L&O<0,L+YL6
M2M\9:/+]IK]X6GEH>\W_UJ_9=T=TK]C],-9=8D*R1.Q=-V%^^&HVNY6CK@I\
MCW'6_?WS_<D#DY=0!MBNH=Z QXLV]U T>[[:++K!B^.*T#B#5>=Z/U5[L\6#
M>9-OML7G:^L:X\'\DN9A78ZYY;ISX)<O'UY\\65;8T/X]+&?TH6[.3IKN_N%
MURV6 6]CO[=85/[!H*)3OJKO/UF PZ*_N@R8+_N9CUS3UN#;I;#6!TG8:=22
MZ#0)L\)GS(7$ZP2D"UEX*$,70D,Q](EJT.^MJLL%34P)$UGWA'5/&!=W:?KE
MD=%;M9[G_?VW\YS&+C'UPB4N8QAD1M\9!?2=$8K%"$HB&('2C^#\US8?^OYU
MKH]J/ZOJ@#4M,O=&H?:/\OX0\+L1BRW4-!'SZ[SXK'>WVHR1M[8:0;_;Y)"[
M\QE%';&N,9S>YN:[P?61M;3T8C]RE[R_*=N\O7F/J[P3H&S_@ TN@T 0.GC&
M%7=,)4%3_#HP'H0P42?:1QPA_T_9'L2!G"X'.^LY"1Y.:".OMU7="_^!],?C
MZJ)LZYOC*N R,RJDJ:,@4-*6RJU@3J>6F32:3+N49Y*/AL</71E$2S)U6L93
M>Q+PO,T+_.-BX[!>6I$8J8' !^V94E*Q#- RD5BMK-)2>CT:*5_L#L)"31V+
M9^HX"0;.X?HDD%9YS&^KU;M ?&:,-N@H>YQVQI!P9DD%IB%F%J)) <:H+'[H
MQ" Z]-3I&$/A2:!R% *EH+G[0Y4]BB6M=.@\G==,B!2$S&C-\YEG(<U"ZF)*
MLLG1,'G"@4&(I%-'9%=E)XJ'7%JN;&H=L( ^92HB,LM#9&@%*A6S:)+QMI4G
M'!B$A_GY\/C_E)T2'L?T]%U]7EV51+CV5ELZ?&$*3&D;&7BN& A,A(^)2+4:
M&XXOY@>A87\2-)ZIZI3 Z,OI=_5975WFI<>E2K@+F""3(B%=G$N8XPY9&KK%
MS]/Y#+*QZ?C&AT&(9#\)(KOH.R5.SJJFA>*_^;8_<^G$6Y/93A!CF/)9RJS"
MP,!0V2UH500UW@GW*0^&M</X3P+)\\5]842Z!?"H1NC]#IAA""%ESH FOZVE
MTBEPIH-PSDF78C(&%%_;'(;!A-NBSQ;PA1/?_<A2G*VK\O,)7&NGG*)RJ.-5
M<8\L"\2P",Y9$P#243H9W]H=!L"$^Z$["?G"$'RL\[;%\KC:;"[*NU-VL]06
M=3 4 %IN*0  !A03$R)D3D@T024CD/"D\6$X3+CAN;ND+\S$AZK(?=[FY>IW
M*GSJ'(HE2$ IO&1T-B+O7:J9<Y P<LY8DVJN8(Q]X;'E831,N,^YHY@OC,)9
MC1W'2&5O_\M?]P-R_2Z2'TLMO>.H(HMI#$P) CJ#C/2)5 %'VN^4=R,@\7T/
MAJ$QX2;G2.)."Y&3IKG ^NM8HH4L4]*Q*+J[4PS7#,!'YE)0*3>!I]D8C<Z_
M\V,8+A-N>(XJ]$MO,>@O:)N\$=*=YVU!9VJ#5#E3M11$C$S))&69$(Z9R!6=
MJ1/O^1BKR;=VAT$QX3;G3D*^, 3G-71WTGVXV;BJ6 ;')7H'C!M,F%+HNS,4
ML-2!%S*5*(T8@8 '1H>E?\*MS.=+.)$%X,VU7T.YPOX>$@094-*1V41#A^>H
M:0'3PM#A&24M9P*"'N.>G*=L#R-APAW+G06=1*?RS0;K%0'][[JZ:M>TW6VA
MO%EZU-9 :E@T&+O&O&,VDD21X.;6.1-QC*7A!RX,NV5K\KW*W>6=!"7')%D-
MQ0F5/M?_P9MEZKT6F0DL2=*41.GZKK%+;Q*XUUQRDXU1/#QI?!@9$VY?[B[I
M"S-Q1-5PZ"KBMP6LEED"(*/@+ 4Z5RNA!;,Z6DIE1!4X>$C&N"GY@=%A#$RX
M@_E\"5\X]_>W))]AG5?A31E^@Q:7J4P5@J(Z2 ?'E =DX+1C:#R$U *Z,$8=
M\:3Q82Q,N'VYNZ2C,?%Z\4C$4[IP^.KNC>ZA^^>.PU?_ U!+ P04    " #
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M/_\#OU]=MZ]//IV<75^5M_W[%QIBK0L,#X!:GI^=-8J<,_5F.KUKI ,(X@>
M]GS 90L23=#P3 F-*']QY<)G]N&*\J;,IJ =Y 6AM4T'$[(>#9?TEZ<=[J%-
M":PVH#>J8_M3Z35T1+DG2HN6GH8]L>SO/X%$2QV<Z[=-7FB2K"UM]C^GKFMW
MVD[B2+(N>VG_<@GL62>^1<0'XDL\V5HO1E4(J]'NM&O&"Q7U/1'UA9-6)+ -
MMX ,%2\(;I#,IIB1X4F2]K.>._7,H[=2LJZX6;RB0Z.L)77:VSYMYIEZJD3[
M6NYCW2(C(8]0PW;ZH*DS@9X.#YUD ,]$SR:>+1$E@^&T=#&!?PYCROTT-#/
M[J%(25WJ2'<_/MZ1 0$\6P<C.<E,L$?4T7;1,3? *"3'DSCDH==Q/XCP'(RN
M)SN/\D57_.I52_$=@)X.L.6_B"9%4X:>G<44E+'.<@:*9^L]\1BA^3+.U&C
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M&(.S-*.E6J05T@NM*'PM"C>TEK&%HTM*3^$/B*;L)%,_\-D#]OX37IHC@[]
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M82TR,#(P,#@P-2YX<V102P$"% ,4    " # @ 51*Q96:XT!  #J @  %0
M            @ '/'P  =FYD82TR,#(P,#@P-5]C86PN>&UL4$L! A0#%
M  @ P( %4>IRH7\0 @  DP8  !4              ( !CR$  '9N9&$M,C R
M,# X,#5?9&5F+GAM;%!+ 0(4 Q0    ( ," !5'MA^U3HPH  *%A   5
M          "  =(C  !V;F1A+3(P,C P.# U7VQA8BYX;6Q02P$"% ,4
M" # @ 51CZ.BD.0&  "J,P  %0              @ &H+@  =FYD82TR,#(P
M,#@P-5]P<F4N>&UL4$L! A0#%     @ P( %47;P4:4>)P  ,($" !D
M         ( !OS4  '9N9&$X+6LX-3(P97AH:6)I=#DY,2YH=&U02P4&
/  < !P#1 0  %%T

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
